Governments must immediately implement the latest WHO guidelines to stop children from dying from this deadly yet curable disease Geneva, 14 November 2023 – Médecins Sans Frontières/Doctors Without Borders (MSF) welcomed the World Health Organization’s (WHO) ‘Roadmap towards ending TB in children and adolescents’ released today, and urged all countries with high TB burdens to prioritise … Read more
The World Health Organization’s (WHO) 2023 Global Tuberculosis (TB) Report released today shows that the estimated global incidence of TB in 2022 remains unacceptably high, including for the more difficult to treat form of this disease, drug-resistant TB (DR-TB). With an estimated 1.3 million people having died from TB in 2022, and still only about … Read more
Since 2001, MSF has been offering free, high-quality counselling services to individuals in Kashmir. To tackle the stigma surrounding mental illness, MSF actively works to raise awareness about the importance of mental health and the necessity for accessible mental health services in the region. Introducing our Mobile Response Team (MRT): a committed group consisting of … Read more
Since 2001, MSF has been offering free, high-quality counselling services to individuals in Kashmir. Our dedicated teams currently operate in hospitals across four districts: Baramulla, Bandipora, Pulwama, and Srinagar. To tackle the stigma surrounding mental illness, MSF actively works to raise awareness about the importance of mental health and the necessity for accessible mental health … Read more
30 September 2023, Geneva Christophe Perrin, TB Advocacy Pharmacist, MSF Access Campaign: “We welcome Johnson & Johnson’s (J&J) announcement finally paving the way for unfettered access to affordable generic versions of bedaquiline for all people living with drug-resistant tuberculosis (DR-TB) who need the drug in low- and middle-income countries. We need all newer TB innovations to be … Read more
TB is curable but remains the world’s leading infectious disease killer 12 September 2023, Geneva/New York – Next week, world leaders meet for the second-ever global tuberculosis (TB) High-Level Meeting at the United Nations (UN) in New York, to endorse ambitious commitments to ramp up TB testing, treatment and prevention in light of innovative medical … Read more
Christophe Perrin, TB advocacy pharmacist, MSF Access Campaign “Today’s announcement by the Stop TB Partnership/Global Drug Facility about a deal with pharmaceutical corporation Johnson & Johnson (J&J), for access to affordable generic versions of the lifesaving tuberculosis (TB) drug bedaquiline, offers a short-term solution for low- and middle-income countries — but the deal remains just a … Read more
With affordable generics likely years away, ViiV must make information public on supply of long-acting cabotegravir and global distribution plan to ensure access for people in high HIV burden low- and middle-income countries Geneva, 30 March 2023 – Today Médecins Sans Frontières/Doctors Without Borders (MSF) called on the pharmaceutical corporation ViiV to immediately provide transparency … Read more
Mumbai, 23 March 2023 – Today, the 2019 patent challenge by two tuberculosis (TB) survivors, Nandita Venkatesan and Phumeza Tisile, was successful: the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly in India on the TB drug bedaquiline beyond the primary patent’s expiry this July. Médecins … Read more
MSF calls on ViiV to urgently dismantle barriers to access for long-acting cabotegravir Geneva, 29 November 2022 – Doctors Without Borders/Médecins Sans Frontières (MSF) today called on pharmaceutical corporation ViiV to urgently dismantle the barriers hindering broad access to the most effective form of HIV pre-exposure prophylaxis (PrEP) that exists, long-acting cabotegravir (CAB-LA), which could … Read more